Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in Ticket the first-line setting.Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evide